Author:
Desai Kanan T.,Alfaro Karla,Mendoza Laura,Faron Matthew,Mesich Brian,Maza Mauricio,Dominguez Rhina,Valenzuela Adriana,DÍaz Acosta Chyntia,MartÍnez Magaly,Felix Juan C.,Masch Rachel,Gabrilovich Sofia,Plump Michael,Novetsky Akiva P.,Einstein Mark H.,Douglas Nataki C.,Cremer Miriam,Wentzensen Nicolas
Abstract
AbstractBackgroundIsothermal amplification-based tests were developed as rapid, low-cost, and simple alternatives to real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-COV-2 detection.MethodsClinical performance of two isothermal amplification-based tests (Atila Biosystems iAMP COVID-19 detection test and OptiGene COVID-19 Direct Plus RT-LAMP test) was compared to clinical RT-PCR assays using different sampling strategies. A total of 1378 participants were tested across four study sites.ResultsCompared to standard of care RT-PCR testing, the overall sensitivity and specificity of the Atila iAMP test for detection of SARS-CoV-2 were 76.2% and 94.9%, respectively, and increased to 88.8% and 89.5%, respectively, after exclusion of an outlier study site. Sensitivity varied based on the anatomic collected site. Sensitivity for nasopharyngeal was 65.4% (range across study sites:52.8%-79.8%), mid-turbinate 88.2%, saliva 55.1% (range across study sites:42.9%-77.8%) and anterior nares 66.7% (range across study sites:63.6%-76.5%). The specificity for these anatomic collection sites ranged from 96.7% to 100%. Sensitivity improved in symptomatic patients (overall 82.7%) and those with a higher viral load (overall 92.4% for ct≤25). Sensitivity and specificity of the OptiGene Direct Plus RT-LAMP test, conducted at a single study-site, were 25.5% and 100%, respectively.ConclusionsThe Atila iAMP COVID test with mid-turbinate sampling is a rapid, low-cost assay for detecting SARS-COV-2, especially in symptomatic patients and those with a high viral load, and could be used to reduce the risk of SARS-COV-2 transmission in clinical settings. Variation of performance between study sites highlights the need for site-specific clinical validation of these assays before clinical adoption.
Publisher
Cold Spring Harbor Laboratory
Reference27 articles.
1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2021 May 11]. Available from: https://covid19.who.int/
2. COVID-19 Vaccine Market Dashboard | UNICEF Supply Division [Internet]. [cited 2021 May 11]. Available from: https://www.unicef.org/supply/covid-19-vaccine-market-dashboard
3. Cancino RS , Su Z , Mesa R , Tomlinson GE , Wang J. The impact of COVID-19 on cancer screening: challenges and opportunities [Internet]. Vol. 6, JMIR Cancer. JMIR Publications Inc.; 2020 [cited 2021 May 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/33027039/
4. In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 | FDA [Internet]. [cited 2021 May 11]. Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular
5. Mitchell SL , St George K , Rhoads DD , Butler-Wu SM , Dharmarha V , McNult P , et al. Understanding, verifying, and implementing emergency use authorization molecular diagnostics for the detection of sars-cov-2 RNA [Internet]. Vol. 58, Journal of Clinical Microbiology. American Society for Microbiology; 2020 [cited 2021 May 11]. Available from: http://jcm.asm.org/
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献